Novartis: positive phase III data in nephropathy
(CercleFinance.com) - Novartis reports positive initial results from its APPLAUSE-IgAN phase III study, with iptacopan demonstrating a clinically and statistically significant reduction in proteinuria in patients with IgA nephropathy (IgAN).
IgAN is a complement-mediated kidney disease, primarily affecting young adults, and is a major cause of chronic kidney disease and renal failure worldwide, the Swiss healthcare group said.
Novartis plans to review these interim (nine-month) results with the FDA to enable a potential regulatory submission for an accelerated approval. The study is ongoing with a final reading (24 months) scheduled for 2025.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
IgAN is a complement-mediated kidney disease, primarily affecting young adults, and is a major cause of chronic kidney disease and renal failure worldwide, the Swiss healthcare group said.
Novartis plans to review these interim (nine-month) results with the FDA to enable a potential regulatory submission for an accelerated approval. The study is ongoing with a final reading (24 months) scheduled for 2025.
Copyright (c) 2023 CercleFinance.com. All rights reserved.